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Abstract 
Ribotoxins constitute a family of toxic extracellular fungal RNases that 
exert a highly specific activity on a conserved region of the larger molecule of 
rRNA, known as the sarcin–ricin loop. This cleavage of a single phosphodiester 
bond inactivates the ribosome and leads to protein synthesis inhibition and cell 
death. In addition to this ribonucleolytic activity, ribotoxins can cross lipid 
membranes in the absence of any known protein receptor. This ability is due to 
their capacity to interact with acid phospholipid-containing membranes. Both 
activities together explain their cytotoxic character, being rather specific when 
assayed against some transformed cell lines. The determination of high-
resolution structures of some ribotoxins, the characterization of a large number 
of mutants, and the use of lipid model vesicles and transformed cell lines have 
been the tools used for the study of their mechanism of action at the molecular 
level. The present knowledge suggests that wild-type ribotoxins or some 
modified variants might be used in human therapies. Production of 
hypoallergenic mutants and immunotoxins designed against specific tumors 
stand out as feasible alternatives to treat some human pathology in the mid-
term future. 
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INTRODUCTION 
 
Ribotoxins are a family of toxic extracellular fungal RNases that exert a 
highly specific ribonucleolytic activity on the larger molecule of rRNA of the 
ribosome leading to protein synthesis inhibition and cell death by apoptosis [1-
4]. They were discovered during a screening program of the Michigan 
Department of Health searching for antibiotics and antitumoral agents. The 
culture filtrates of a mould identified as Aspergillus giganteus MDH18894 
contained a substance inhibitory to sarcoma and carcinoma induced in mice [5]. 
The molecule responsible for these effects was proved to be a protein, named 
α-sarcin, that still today is the best known ribotoxin (Fig. 1A) [6]. Unfortunately, 
the rather unspecific cytotoxicity of these proteins when administered to animals 
harboring different tumors limited their potential clinical use [7]. 
α-Sarcin, restrictocin, and Asp f 1 are the most exhaustively 
characterized ribotoxins [1-4,8-10], but many others have been identified and 
partially characterized in different fungal species [11-16], including the 
insecticidal protein hirsutellin A (HtA) produced by the invertebrate fungal 
pathogen Hirsutella thompsonii [15,17,18]. All ribotoxins show a high degree of 
amino acid sequence identity (above 85%) with precisely the only exception of 
HtA that displays only about 25% sequence identity with the previously known 
family members [15,18]. 
Ribotoxins are not the only extracellular RNases produced by fungi. For 
example, a mould so common as Aspergillus oryzae, that is used in the 
production of various comestible foods, is also the producer of RNase T1 [19], 
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probably one of the most exhaustively characterized proteins. RNase T1 is 
therefore the best known member of the family of fungal extracellular RNases 
[20,21], a group that obviously includes ribotoxins. All of them also show a high 
degree of sequence [15,16,22,23] and structural similarity [24-29] but, apart 
from ribotoxins, none of these other fungal RNases has been reported to show 
cytotoxic activity. 
In addition to RNase T1, RNase U2 from Ustilago sphaerogena also 
deserves to be mentioned because it is the non-toxic fungal extracellular RNase 
most closely related to ribotoxins of from a phylogenetic point of view 
[3,15,16,23,30]. RNase U2 is a small and highly acidic protein [31] that shows a 
strong preference for 3’-linked purine nucleotide phosphodiester bonds [32,33], 
specificity that is rather unusual within the group of microbial RNases. The 
observation that ribotoxins are larger basic proteins, containing longer and 
charged loops that are not present in the non-cytotoxic fungal RNases, 
suggested that these loops are directly related to their cytotoxic properties [30]. 
It would appear that an RNase T1-like protein would have acquired ribosome 
specificity by the insertion of short recognition domains that would target it to 
cleave more specific substrates. This hypothesis has become even more 
appealing after the recent biochemical characterization of HtA [18], a much 
smaller ribotoxin presumably with shorter loops.  
In summary, all the features outlined above suggest that the study of the 
evolution and the mechanism of action of ribotoxins is of particular interest, as 
they appear to be naturally engineered targeted toxins evolved from the other 
microbial nontoxic RNases to enter cells and specifically inactivate the 
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ribosomes [34,35]. Identification of the structural features that have allowed 
these proteins to become such efficient natural killers would be a major step 
towards their utilization, native or modified, as weapons against different human 
pathologies. 
 
RIBONUCLEOLYTIC ACTIVITY 
 
Ribotoxins inhibit protein biosynthesis in ribosomal preparations by 
specifically cleaving a single phosphodiester bond of the large rRNA fragment 
[36,37]. This bond is also the specific target of the plant family of N-
glycosidases known as ribosome-inactivating proteins (RIP) [38,39] best 
represented by ricin, the toxin found in the seeds from the castor bean plant, 
Ricinus communis. This region, known as the sarcin–ricin loop or SRL (Fig. 2) is 
unique and it is located at an evolutionarily conserved site with important roles 
in ribosome function [40]. 
Ribotoxins behave as highly specific RNases when assayed against cell-
free intact ribosomes, retaining this specificity when assayed against naked 
rRNA containing the SRL sequence. However, they can also produce extensive 
non-specific digestion of almost any RNA when used at higher concentrations 
[9,41]. Ribotoxins follow the same general acid–-base type endonucleolytic 
reaction scheme as the other members of the RNase T1 family [2,3,42,43]. 
First, there is a transphosphorylation reaction to form a 2’,3’-cyclic phosphate 
intermediate. Second, this intermediate is hydrolyzed to the corresponding 3’-
phosphate. The appearance of this cyclic intermediate, common to all proteins 
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of the RNase T1 family so far studied is implicit in the denomination of all these 
enzymes as cyclizing RNases [43]. However, the catalytic efficiency of RNases 
T1 and U2 against naked RNA, homopolynucleotides, or dinucleotides is 
several orders of magnitude higher. On the other hand, ribotoxins cleave and 
consequently inactivate the ribosome with a second order rate constant that 
matches the catalytic efficiency of the fastest known enzymes [44]. 
In the case of α-sarcin, during the first step of the reaction, Glu-96 acts 
as a general base and His-137 as a general acid. The hydrolysis of the cyclic 
derivative is then catalyzed by the same groups, but their roles are reversed 
[43,45]. In fact, this Glu/His combination is the most common pair of catalytic 
residues found in microbial RNases [20]. Another conserved residue, His-50, is 
required to assist the electrostatic stabilization of the transition state [45]. 
Mutational studies have also revealed that three other active site residues, 
Tyr48, Arg121, and Leu145, although not essential, appear to be determinants 
of the ribotoxin activity of α-sarcin [46-48]. Studies on the crystal structures of 
complexes of restrictocin with inhibitors led to the proposal that these ribotoxins 
may use base flipping to enable cleavage at the correct site of the SRL 
substrates [49]. All studies so far suggest that these three residues would 
enable the base flipping performed by His50/Glu96/His137 that permits 
cleavage of the unique phosphodiester bond at the SRL [49]. 
 
INTERACTION WITH PHOSPHOLIPIDS 
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In addition to their ribonucleolytic activity, ribotoxins cross lipid 
membranes in the absence of any known protein receptor [1,3,50]. Thus, 
although any ribosome could be potentially inactivated by these proteins, due to 
the universal conservativeness of the SRL, they are especially active on 
transformed or virus-infected cells [5,51,52]. This observation has been 
explained in terms of an altered permeability of their target cells combined with 
the ability of ribotoxins to interact with acid phospholipid-containing membranes 
[3,4,52-54]. Indeed, this ability seems to be related to the antitumoral character 
that led to their discovery [5,55]. 
In this regard, the use of lipid model systems proved that α-sarcin 
specifically interacts with negatively charged phospholipid vesicles at neutral or 
slightly acidic pH, resulting in protein–lipid complexes that can be isolated by 
centrifugation in a sucrose gradient [53]. Binding experiments revealed a strong 
ribotoxin–lipid vesicle interaction that caused vesicle aggregation, followed by 
their fusion into much larger lipidic structures [53]. Indeed, the peptide bonds of 
the protein were protected against trypsin hydrolysis upon binding to these 
vesicles [53,55], despite the high number of basic residues present along its 
sequence [23]. Altogether, all these results proved how α-sarcin, a water-
soluble and hydrophilic protein, can interact with phospholipid bilayers through a 
combination of electrostatic and hydrophobic forces [56]. In good agreement 
with this scenario, the innate ability of α-sarcin to translocate across a 
phospholipid membrane in the absence of any other protein has also been 
demonstrated [50]. 
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The current working hypothesis sustains that a higher content of 
negatively charged phospholipids in transformed cell membranes [53,54,57-60] 
would explain the favored toxicity of these proteins against tumors. 
Unfortunately, there is no direct evidence yet that this abundance of acidic 
phospholipids is the main explanation for the antitumoral activity of α-sarcin. 
 
STRUCTURAL FEATURES 
 
As mentioned above, ribotoxins show a high degree of identity in their 
approximately 150 amino acid sequence [14-16,23,61-64], including the 
conservation of their two disulfide bridges [3,30]. This observation includes HtA 
[15,18], although this protein is 20 residues shorter than most of the other 
known ribotoxins. Sequence differences are mainly concentrated at the loops of 
the ribotoxins suggesting that these differences are responsible for the minor 
differences observed among their activities [15]. 
This similarity is also evident between the two ribotoxins whose three-
dimensional structure has been solved, restrictocin [26,49] and α-sarcin [29,65-
67]. Both proteins folds into a common α + β structure with a central five-
stranded antiparallel β-sheet and an α-helix of almost three turns. Residues 1–
26 are especially interesting because they form a long β-hairpin that can be 
considered as two consecutive minor β-hairpins connected by a hinge region 
(Fig. 1A). The distal region of this β-hairpin has been deleted, obtaining the 
Δ(7–22) variant of α-sarcin [68], a mutant retaining the same conformation as 
the wild-type protein (Fig. 1B) [69]. Further support for the importance of this N-
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terminal extension was obtained by docking and enzymatic studies which 
revealed that this β-hairpin most probably establishes interactions with specific 
ribosomal proteins in order to direct the ribotoxin to the SRL [67, 68]. This 
prediction would also explain the highly diminished cytotoxic properties 
observed for the deleted variant [68]. 
Even though α-sarcin and restrictocin show almost identical structures, 
some small but nevertheless significant functional and structural differences are 
evident. These differences concern the long non-structured loops and especially 
the N-terminal β-hairpin, a region of high mobility [26,65]. Interestingly, these 
aperiodic loops show a well defined conformation despite their exposed 
character and their lack of repetitive secondary structure [65]. 
Ribotoxins share their structural core with the non-toxic RNases of the 
RNase T1 family, in good agreement with their sequence similarities. Both 
RNase T1 and RNase U2 display identical regular secondary structure 
elements to ribotoxins despite their different amino acid sequence lengths. The 
geometric arrangement of the residues involved in the active site is also shared 
by both families of RNases. In fact, all fungal extracellular RNases whose three-
dimensional structure is known exhibit quite different enzymatic specificities, but 
all of them share this common structural fold concerning the architecture and 
connectivity of the secondary structure elements [3,26,28,29]. The most 
significant structural differences among them are, again, related to both the 
presence of the longer N-terminal β-hairpin in ribotoxins and the different length 
and charge of their aperiodic loops. 
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In addition to the deletion mutant mentioned above, many more α-sarcin 
mutants have been isolated and characterized. These mutational studies have 
revealed the involvement of several residues, which are conserved among the 
different microbial extracellular RNases, in catalysis. Thus, it is well known that 
His137 and Glu96 are the only residues that are essential for the cleavage 
reaction performed by α-sarcin [35,45,70-75], whereas His-50, Tyr-48, Arg-121, 
and Leu-145 mostly contribute to the stabilization of the transition state [45-48], 
as stated above. Most of these residues are located in the central β-sheet and 
their side-chains point towards the concave face of the protein structure where 
the substrate is supposed to dock [29]. 
With regard to the protein regions involved in the interaction with 
membranes, the use of water-soluble synthetic peptides and mutant variants of 
α-sarcin within the main β-sheet of this protein suggested that this region 
(residues 116–139) would be directly involved in this interaction [76-78]. 
Interestingly, this sheet has also been predicted to be one of the few apolar 
regions of the protein [30,76]. The study of the mentioned mutants suggested 
that it would be located within the hydrophobic core of the phospholipid bilayer 
once the protein-lipid complexes were formed [46,78]. Within this same idea, 
mutants affecting α-sarcin active site residue Arg121 (R121K and R121Q), 
showed that the loss of the positive charge at that position produced a dramatic 
impairment of the protein’s ability to interact with phospholipid membranes [46]. 
Other than this hydrophobic core, mutations affecting single residues located at 
the N-terminal β-hairpin of α-sarcin and the Δ(7–22) variant suggested that this 
protein portion would also be another region involved in the interaction with cell 
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membranes, as they display a different pattern of interaction with lipid vesicles 
[68,79]. Finally, loop 2 has been proposed by several authors [26,29,30,72] to 
be also one of the protein regions involved in the interaction with lipids but this 
possibility has not been directly studied yet. 
 
CYTOXICITY AGAINST INTACT CELLS 
 
α-Sarcin is able to inactivate the ribosomes of a great variety of 
organisms in cell-free systems [4,35], but it displays marked selectivity when 
intact cells are used as targets. This specificity seems to be determined by its 
ability to penetrate cells, as explained above. Thus, α-sarcin is especially active 
against transformed or virus-infected mammalian cells in the absence of any 
other permeabilizing agent [51,52,80-83]. This effect is saturable and consistent 
with passage across the cell membrane as the rate-limiting step. However, no 
membrane damage or mitochondrial activity alterations are detected [82]. These 
experiments confirmed that α-sarcin exhibits an intrinsic and rather specific 
cytotoxic character when assayed against some transformed cell lines, most 
probably due to the presence of acidic phospholipids on the outer leaflet of the 
membrane [53,54,57,58]. Consequently, all α-sarcin mutants studied that 
displayed an altered phospholipid interaction ability, such as that one affecting 
the positive charge of the active site residues Arg-121 (R121Q) [46] or, again, 
the Δ(7–22) deletion mutant [68], showed diminished cytotoxic effects on 
human rhabdomyosarcoma cells [68,79]. Obviously, mutation of the catalytically 
essential His-137 (H137Q) rendered a non-cytotoxic variant too [52]. 
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THE A. FUMIGATUS ALLERGEN Asp f 1 
 
Fungi represent one of the principal sources of allergens. Invasive 
infection is usually fatal unless treated early, and even then, antifungal therapy 
is often unsuccessful. The incidence of fungal infections has indeed risen lately, 
owing to the increase in the number of immunocompromised patients [84]. 
Furthermore, a link between fungal allergy and severe asthma is accepted, 
although still poorly understood [85,86]. Aspergillus fumigatus is an 
opportunistic human pathogen and one of the most common sources of allergy 
and asthma in humans [87,88]. This fungus is also the producer of Asp f 1, a 
ribotoxin and one of its most important allergens [8,64]. Asp f 1, for example, 
has been found in the urine of patients with disseminated aspergillosis 
[8,64,89], although it has also been proven that it is not a major virulence factor 
in A. fumigatus infections [90-92]. However, this protein is clearly involved in the 
pathogenicity of allergic bronchopulmonary aspergillosis (ABPA), the most 
severe form of allergic inhalant diseases, as these patients show high levels of 
Asp f 1-specific IgE [10,93]. 
Extracts of A. fumigatus are frequently used to diagnose allergic 
reactions, but they are highly complex mixtures very difficult to standardize [94]. 
Attempts to improve diagnosis are focusing on the use of homogeneous 
standard preparations of recombinantly produced allergens [95,96]. 
Unfortunately, recombinant native Asp f 1 is not devoid of cytotoxic activity, and 
indeed it can trigger anaphylaxis. Taking into account that the ribotoxin-
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characteristic N-terminal β-hairpin shows high amino acid sequence variability 
[3,15,16] and that it is highly flexible and exposed [29,69], it was considered as 
a major determinant of the immunoreactivity of these proteins [10]. This 
hypothesis was confirmed through the production and characterization of 
Asp f 1, α-sarcin, and their corresponding Δ(7–22) variants [10,68]. The two 
deleted proteins studied showed marked decreases in their reactivity to Asp f 1-
IgE antibodies, suggesting that this N-terminal β-hairpin was involved in at least 
one allergenic epitope [10]. In addition, these experiments reinforced the 
significant prevalence of Asp f 1-specific IgE antibodies in sera from ABPA 
patients sensitized to A. fumigatus [2,10,96,97]; a prevalence that was also 
observed for the Asp f 1 variants studied that, even more importantly, also 
retained most of the IgG epitopes [10]. 
The amount of data accumulated with these noncytotoxic deletion 
variants of Asp f 1 seems to favor their use in immunomodulating therapies for 
Aspergillus hypersensitivity and diagnosis, although in vivo assays are still 
required to assess this possibility. Within this idea, it must be remarked how 
these potentially hypoallergenic ribotoxin molecules have been recently cloned 
and produced in Lactococcus lactis [98], a microorganism ‘generally regarded 
as safe’ (GRAS). This GRAS status of L. lactis, altogether with the fact that the 
hypoallergenic variants of Asp f 1 are secreted by the engineered bacteria, 
confers this system with the features required to try immunotherapeutic 
protocols for Asp f 1-related allergic diseases. The feasibility of this approach 
will be next tested in animal models in our laboratory after the recent 
optimization of an allergic murine model sensitized against this allergen 
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[Álvarez-García, E.; Batanero, E.; García-Fernández, R.; Villalba, M.; 
Rodríguez, R.; Gavilanes, J.G. and Martínez del Pozo, A., unpublished data]. 
 
RIBOTOXINS AS PART OF IMMUNOTOXINS 
 
Immunotoxins are therapeutic agents with a high degree of specificity, 
composed of targeting moieties, such as antibodies or physiologically important 
ligands, linked to toxic proteins [99-101]. The design of this type of molecules is 
helping to close the gap required to achieve one of the oldest goals of 
antitumoral therapy, proposed by Ehrlich as early as 1906, of targeting cancer 
cells with a ‘magic bullet’ consisting of a tissue-specific carrier that would deliver 
toxic agents to neoplastic tissue [102]. Initially, immunotoxins were prepared by 
conjugating toxins to monoclonal antibodies, using the whole antibody molecule 
as targeting moiety [103]. However, it was soon realized that smaller sizes 
would allow higher index of penetration within solid tumors, easier clearance 
from blood vessels, and easier manipulation procedures. Within this idea, new 
approaches have been optimized with the advent of the late extraordinary 
biotechnological development, including the production of recombinant 
immunotoxins in different model organisms such as bacteria, yeast, or even 
insect cells [author(s), unpublished data]. This type of molecules is considered 
as a second generation of immunotoxins that contain only the antibody variable 
domains stabilized by a flexible peptide (scFv) or a disulfide bridge (dsFv) (Fig. 
3) [104,105]. 
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Regarding the toxic moiety, the most representative toxins employed 
have been ricin from plants [106-110] and Pseudomonas exotoxin A or 
diphtheria toxin from bacteria [111-116]. However, although not so frequently 
employed, ribotoxins have several advantages for their use in the design of 
immunotoxins; namely, their small size, high thermostability, poor 
immunogenicity, resistance to proteases, and their highly efficient ability to 
inactivate ribosomes [3,4,117]. In fact, different ribotoxins have been used as 
components of immunotoxins [117-125]. The first ribotoxin-based immunotoxins 
were constructed by chemical conjugation with mitogillin [122], restrictocin [117-
119], or α-sarcin [121]. Some years later second-generation versions were also 
produced by fusing restrictocin cDNA with that encoding the scFv region of a 
monoclonal antibody directed against the human transferrin receptor, joined by 
a linear flexible peptide to promote the independent folding of the two 
immunotoxin moieties. These constructs were further engineered to enhance 
the intracellular processing and delivery of the ribotoxin [126]. Unfortunately, 
none of these ribotoxin-based immunotoxins has been yet studied beyond a 
preliminary characterization, most probably due to their large size, which could 
hinder their correct internalization into solid tumors, or to the low structural 
stability of the immunoconjugates prepared. 
Much more recently, a new ribotoxin-based immunotoxin approach 
aimed at solving these problems has been developed. Within this idea, a single-
chain immunotoxin composed of the variable domains of the B5 monoclonal 
antibody bound to α-sarcin through a peptide containing a furin cleavage site 
(scFv-IMTXαS) (Fig. 3) has been efficiently produced in the methylotrophic 
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yeast Pichia pastoris [Carreras-Sangrà, N.; Martínez del Pozo, A.; Oñaderra, 
M.; Gavilanes, J.G. and Lacadena, J., unpublished data]. The B5 LewisY 
monoclonal antibody, a member of the Nemod antibody family, is specific 
against LewisY carbohydrates. These tumor-associated antigens are 
overexpressed on the surface of many carcinomas, including breast and colon 
solid tumors [127]. Various members of this family of antibodies have already 
been used as targeting moieties in many different immunotoxins [127-134] and 
at least three of them have been tested in phase I trials in patients with cancer 
yielding promising favorable results [130,135]. 
P. pastoris has emerged as a convenient robust heterologous expression 
host for immunotoxin production due to its efficient secretory system and its 
ability to express complex recombinant proteins with correct intra and 
intermolecular disulfide bonds. The constructs expressed in this system usually 
produce proteins that do not require additional in vitro unfolding and refolding 
steps, unlike most of the immunotoxins heterologously expressed in bacteria 
[136-138]. Indeed, P. pastoris possesses tightly regulated promoters such as 
that of the alcohol oxidase 1 gene (AOX1), which is perfectly suited for the 
controlled expression of foreign genes [139]. This explains why P. pastoris was 
the microorganism chosen to produce recombinant scFv-IMTXαS. The 
immunotoxin produced with this system displays the characteristic 
ribonucleolytic activity of α-sarcin as well as specific cytotoxicity against cell 
lines containing the LewisY antigen [Carreras-Sangrà, N.; Martínez del Pozo, A.; 
Oñaderra, M.; Gavilanes, J.G. and Lacadena, J., unpublished data]. Binding 
assays performed with different cellular extracts, with a commercial version of 
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the LewisY antigen, or with a synthetic peptide with such a structure that mimics 
the antigen behavior, have confirmed the high specific affinity conferred to the 
immunotoxin by its targeting moiety. With the aim to obtain a more cytotoxic 
immunotoxin, different approaches and designs have been assayed in order to 
improve toxin delivery into the cytosol of the targeted cells or to increase the 
stability and/or affinity of the immunotoxin [Carreras-Sangrà, N.; Martínez del 
Pozo, A.; Oñaderra, M.; Gavilanes, J.G. and Lacadena, J., unpublished data]. 
The immunoribotoxins constructed by these means appear to be potential good 
candidates to be studied in the field of cancer therapies. 
 
CONCLUSIONS AND FUTURE PROSPECTS 
 
Ribotoxins are unique RNases displaying an exquisite specific 
ribonucleolytic action as well as an innate ability to cross membranes. Both 
activities altogether explain the antitumoral properties that led to their discovery. 
The initial deception produced by the abandonment of their use as potential 
anticancerous agents in human therapies has been slowly overcome through 
the detailed study of their mechanism of action at the molecular level for many 
years [1-4,9,34]. In this regard, the determination of several high-resolution 
ribosomal structures, the characterization of a great variety of mutants, and the 
use of different lipid model vesicles and transformed cell lines have been of 
great help. Thus, the current knowledge about their mechanism of action 
suggests that these ribotoxins, or probably some of their modified variants, 
might be used soon with therapeutic aims. Within this idea, the production of 
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hypoallergenic variants to treat fungal allergies and different immunotoxins 
designed against specific tumors stand out as the most feasible alternatives in 
the mid-term future. 
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Fig. (1) Three-dimensional structures of (A) wild-type (PDB ID 1DE3) and (B) 
Δ(7-22) (PDB ID 1R4Y) α-sarcins [29,69]. The diagrams were generated with 
the VMD program [140]. 
 
Fig. (2) Diagram showing the structure of the SRL (PDB ID 430d) [141]. 
Numbers correspond to rat or Escherichia coli (in brackets) nucleotide positions 
within the 28S (23S) rRNA gene. The bond cleaved by ribotoxins is that on the 
3’-side of G4325 (2661). Ricin depurinates A4324 (2660). Both nucleotides 
have been represented in a darker gray tone. The bulged G is G4319 (2655). 
The diagram was generated with the VMD program [140]. 
 
Fig. (3) Scheme showing the different immunotoxin designs constructed using 
modified versions of the B5 LewisY monoclonal antibody and the ribotoxin α-
sarcin. CDR, complementary determining regions; VH, variable domain of high 
chain; VL, variable domain of light chain; S-S, disulfide bridge; FR2, framework 
region 2. 



